Prognostic role of docetaxel-induced suppression of free testosterone serum levels in metastatic prostate cancer patients

Abstract To date, only few data concerning the biologically active, free form of testosterone (FT) are available in metastatic prostate cancer (mPC) and the impact of FT on disease, therapy and outcome is largely unknown. We retrospectively studied the effect of docetaxel on FT and total testosteron...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Paula Kappler, Michael A. Morgan, Philipp Ivanyi, Stefan J. Brunotte, Arnold Ganser, Christoph W. M. Reuter
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/a789714755e147bb96b1cf2cae3cdbfa
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a789714755e147bb96b1cf2cae3cdbfa
record_format	dspace
spelling	oai:doaj.org-article:a789714755e147bb96b1cf2cae3cdbfa2021-12-02T16:28:50ZPrognostic role of docetaxel-induced suppression of free testosterone serum levels in metastatic prostate cancer patients10.1038/s41598-021-95874-y2045-2322https://doaj.org/article/a789714755e147bb96b1cf2cae3cdbfa2021-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-95874-yhttps://doaj.org/toc/2045-2322Abstract To date, only few data concerning the biologically active, free form of testosterone (FT) are available in metastatic prostate cancer (mPC) and the impact of FT on disease, therapy and outcome is largely unknown. We retrospectively studied the effect of docetaxel on FT and total testosterone (TT) serum levels in 67 mPC patients monitored between April 2008 and November 2020. FT and TT levels were measured before and weekly during therapy. The primary endpoint was overall survival (OS). Secondary endpoints were prostate-specific antigen response and radiographic response (PSAR, RR), progression-free survival (PFS), FT/TT levels and safety. Median FT and TT serum levels were completely suppressed to below the detection limit during docetaxel treatment (FT: from 0.32 to < 0.18 pg/mL and TT: from 0.12 to < 0.05 ng/mL, respectively). Multivariate Cox regression analyses identified requirement of non-narcotics, PSAR, complete FT suppression and FT nadir values < 0.18 pg/mL as independent parameters for PFS. Prior androgen-receptor targeted therapy (ART), soft tissue metastasis and complete FT suppression were independent prognostic factors for OS. FT was not predictive for treatment outcome in mPC patients with a history of ART.Paula KapplerMichael A. MorganPhilipp IvanyiStefan J. BrunotteArnold GanserChristoph W. M. ReuterNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Paula Kappler Michael A. Morgan Philipp Ivanyi Stefan J. Brunotte Arnold Ganser Christoph W. M. Reuter Prognostic role of docetaxel-induced suppression of free testosterone serum levels in metastatic prostate cancer patients
description	Abstract To date, only few data concerning the biologically active, free form of testosterone (FT) are available in metastatic prostate cancer (mPC) and the impact of FT on disease, therapy and outcome is largely unknown. We retrospectively studied the effect of docetaxel on FT and total testosterone (TT) serum levels in 67 mPC patients monitored between April 2008 and November 2020. FT and TT levels were measured before and weekly during therapy. The primary endpoint was overall survival (OS). Secondary endpoints were prostate-specific antigen response and radiographic response (PSAR, RR), progression-free survival (PFS), FT/TT levels and safety. Median FT and TT serum levels were completely suppressed to below the detection limit during docetaxel treatment (FT: from 0.32 to < 0.18 pg/mL and TT: from 0.12 to < 0.05 ng/mL, respectively). Multivariate Cox regression analyses identified requirement of non-narcotics, PSAR, complete FT suppression and FT nadir values < 0.18 pg/mL as independent parameters for PFS. Prior androgen-receptor targeted therapy (ART), soft tissue metastasis and complete FT suppression were independent prognostic factors for OS. FT was not predictive for treatment outcome in mPC patients with a history of ART.
format	article
author	Paula Kappler Michael A. Morgan Philipp Ivanyi Stefan J. Brunotte Arnold Ganser Christoph W. M. Reuter
author_facet	Paula Kappler Michael A. Morgan Philipp Ivanyi Stefan J. Brunotte Arnold Ganser Christoph W. M. Reuter
author_sort	Paula Kappler
title	Prognostic role of docetaxel-induced suppression of free testosterone serum levels in metastatic prostate cancer patients
title_short	Prognostic role of docetaxel-induced suppression of free testosterone serum levels in metastatic prostate cancer patients
title_full	Prognostic role of docetaxel-induced suppression of free testosterone serum levels in metastatic prostate cancer patients
title_fullStr	Prognostic role of docetaxel-induced suppression of free testosterone serum levels in metastatic prostate cancer patients
title_full_unstemmed	Prognostic role of docetaxel-induced suppression of free testosterone serum levels in metastatic prostate cancer patients
title_sort	prognostic role of docetaxel-induced suppression of free testosterone serum levels in metastatic prostate cancer patients
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/a789714755e147bb96b1cf2cae3cdbfa
work_keys_str_mv	AT paulakappler prognosticroleofdocetaxelinducedsuppressionoffreetestosteroneserumlevelsinmetastaticprostatecancerpatients AT michaelamorgan prognosticroleofdocetaxelinducedsuppressionoffreetestosteroneserumlevelsinmetastaticprostatecancerpatients AT philippivanyi prognosticroleofdocetaxelinducedsuppressionoffreetestosteroneserumlevelsinmetastaticprostatecancerpatients AT stefanjbrunotte prognosticroleofdocetaxelinducedsuppressionoffreetestosteroneserumlevelsinmetastaticprostatecancerpatients AT arnoldganser prognosticroleofdocetaxelinducedsuppressionoffreetestosteroneserumlevelsinmetastaticprostatecancerpatients AT christophwmreuter prognosticroleofdocetaxelinducedsuppressionoffreetestosteroneserumlevelsinmetastaticprostatecancerpatients
_version_	1718383947070570496

Prognostic role of docetaxel-induced suppression of free testosterone serum levels in metastatic prostate cancer patients

Ejemplares similares